MannKind Corporation announced that the US Food and Drug Administration (FDA) has accepted and filed MannKind's New Drug Application (NDA) for Afresa, an ultra rapid-acting insulin. MannKind is seeking FDA approval of Afresa for the treatment of adults with type-1 or type-2 diabetes mellitus for the control of hyperglycaemia.
Afresa is a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patients with type-1 and type-2 diabetes mellitus for the treatment of hyperglycaemia.
MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.